WAM
PACB icon

Wealthspire Advisors (Maryland)’s Pacific Biosciences PACB Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,300
Closed -$9K – 1540
2019
Q1 		$9K Buy
+1,300
New +$9.4K ﹤0.01% 1585

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s PACB Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Pacific Biosciences (PACB) in Q2 2019, closing a stake of 1,300 shares — an estimated $9K sold.

Wealthspire Advisors (Maryland) first reported a position in PACB in Q1 2019 and held it in 1 quarter. The position peaked at $9K in Q1 2019. 150 funds tracked by Wall St. Rank hold PACB as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Pacific Biosciences position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 1,300 Pacific Biosciences shares in Q2 2019, an estimated $9K.
  • Wealthspire Advisors (Maryland) first reported a position in Pacific Biosciences in Q1 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Pacific Biosciences position peaked at $9K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.